NORTHCLIFF ANNOUNCES CLOSING OF $1.2 MILLION PRIVATE PLACEMENT FINANCING
About Northcliff Resources Ltd.
Northcliff is a mineral resource company focused on advancing the feasibility-stage Sisson Tungsten-Molybdenum Project located in New Brunswick, Canada , to production.
Additional information on Northcliff is available on the website at www.northcliffresources.com. Investor services can be reached at (604) 684-6365 or within North America at 1-800-667-2114.
Andrew Ing
Chairman, President & CEO
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
5 minutes ago
- CTV News
Nova Scotia looks to carry out passenger rail feasibility study
The Government of Nova Scotia announced Tuesday it is looking for qualified consultants to carry out a study on passenger rail feasibility. The study was identified as a key action in the province's Regional Transportation Plan, released by Link Nova Scotia on Aug. 6. The plan was developed to look at long-term strategies to manage transportation as the province's population continues to grow. 'Passenger and light rail has the potential to reshape travel for Nova Scotians by providing a safe, reliable and high-capacity form of transit service,' said Public Works Minister Fred Tilley. 'While a project like this could be transformative, it's also incredibly complex. The passenger rail feasibility study will ensure that any decisions related to rail in the province are researched, evidence-based and tailored for Nova Scotians.' A news release from the province says the study will assess potential opportunities and challenges associated with light rail transit in the municipality and passenger rail in the broader region. The study will: evaluate and screen possible regional and urban corridors advance conceptual designs for options in the selected corridors provide an evidence-based evaluation of options include a long-term transit phasing strategy to support growth, network resiliency and strategic corridor preservation Qualified firms can submit their response before Sept. 16. For more Nova Scotia news, visit our dedicated provincial page
CTV News
5 minutes ago
- CTV News
Ottawa signs agreement with Toronto-based artificial intelligence company
Aidan Gomez, co-founder of Cohere, attends the Collision Conference in Toronto on Tuesday, June 18, 2024. (THE CANADIAN PRESS/Chris Young) The Canadian government has signed a memorandum of understanding with a Toronto-based artificial intelligence startup. The MOU between Ottawa and Cohere Inc. aims to promote Canadian AI technologies and explore how AI can be used to enhance government operations. Newly elected MP and former journalist Evan Solomon is Canada's Minister of Artificial Intelligence and Digital Innovation and Minister responsible for the Federal Economic Development Agency for Southern Ontario. 'There's no better place to leverage the innovative technology of artificial intelligence than here in our own backyard, and no better use than in the service of Canadians from coast to coast to coast,' Solomon said in a news release. 'By working with Canadian AI innovators like Cohere, we're laying the groundwork for a more efficient, effective and productive public service while helping ensure that Canada remains competitive in this new digital era.' Founded in 2019, Cohere, which has a US$6.8-billion valuation, builds AI models and has partnered with Canadian and international companies such as Dell, Oracle, RBC and Bell. 'AI will supercharge economic productivity, fortify national security and future-proof Canada's competitiveness,' Cohere CEO Aidan Gomez said in the news release. 'That's why building this technology and developing the next generation of AI talent right here in Canada is essential.' Prime Minister Mark Carney's government has emphasized the economic potential of AI and has committed to investing in AI training, adoption and commercialization. 'This MOU with Cohere is an opportunity to explore how sovereign AI can strengthen public services, protect our digital sovereignty and create opportunities for Canadians,' Joël Lightbound, minister of government transformation, public works and procurement, said in the news release. 'By engaging with home-grown innovators, we can better understand and harness the potential of these technologies, ensure they are developed and deployed responsibly, and help position the Government of Canada as a strong market for Canadian AI solutions.' With files from The Canadian Press CTV News, CP24 and BNN Bloomberg are owned by Bell Media, which is a division of BCE.
Globe and Mail
29 minutes ago
- Globe and Mail
NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, reported financial results for the quarter ended June 30, 2025, and provided a corporate update. The Company highlighted progress in all three lead programs, including expanded FDA Fast Track designation for NRX-100 in treating suicidal depression, filing of multiple regulatory documents, and advancement of the NRX-101 NDA. A strategic investor group led by B Group Capital has committed capital through a purchase of restricted common stock with a one-year lockup and no dilutive mechanisms. The capital is expected to support the Company through key regulatory milestones and help scale HOPE Therapeutics and its clinic network. To view the full press release, visit About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression; the company recently filed module 3 manufacturing data to support the New Drug Application for NRX-101. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner's National Priority Voucher Program for the treatment of suicidal depression. The filing is based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and the Government of France, licensed under a data sharing agreement. NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Corporate Communications
